Norovirus Vaccine (Virus-Like Particles) from Canada
Bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate using recombinant technology. HTS 3002.49.00 covers biotechnological immunological products as 'other' vaccines. Intramuscular administration.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Provide biotech process validation documents
• Classify as vaccine, not reagent per chapter note 4(d)
• Monitor for clinical trial kit repackaging to 3006